SK283417B6 - Farmaceutický prostriedok, spôsob jeho prípravy a použitie - Google Patents

Farmaceutický prostriedok, spôsob jeho prípravy a použitie Download PDF

Info

Publication number
SK283417B6
SK283417B6 SK1299-99A SK129999A SK283417B6 SK 283417 B6 SK283417 B6 SK 283417B6 SK 129999 A SK129999 A SK 129999A SK 283417 B6 SK283417 B6 SK 283417B6
Authority
SK
Slovakia
Prior art keywords
pharmaceutical composition
lamivudine
composition according
pharmaceutically acceptable
treatment
Prior art date
Application number
SK1299-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK129999A3 (en
Inventor
Warren Michael Casey
Ngoc-Anh Thi Nguyen
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9706295.4A external-priority patent/GB9706295D0/en
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of SK129999A3 publication Critical patent/SK129999A3/sk
Publication of SK283417B6 publication Critical patent/SK283417B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1299-99A 1997-03-24 1998-03-20 Farmaceutický prostriedok, spôsob jeho prípravy a použitie SK283417B6 (sk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4235397P 1997-03-24 1997-03-24
GBGB9706295.4A GB9706295D0 (en) 1997-03-26 1997-03-26 Lamivudine formulation
PCT/EP1998/001626 WO1998042321A2 (en) 1997-03-24 1998-03-20 Liquid compositions comprising lamivudine

Publications (2)

Publication Number Publication Date
SK129999A3 SK129999A3 (en) 2000-07-11
SK283417B6 true SK283417B6 (sk) 2003-07-01

Family

ID=26311267

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1299-99A SK283417B6 (sk) 1997-03-24 1998-03-20 Farmaceutický prostriedok, spôsob jeho prípravy a použitie

Country Status (40)

Country Link
US (1) US6004968A (pl)
EP (1) EP0969815B1 (pl)
JP (1) JP3264937B2 (pl)
KR (1) KR100484695B1 (pl)
CN (1) CN1191061C (pl)
AP (1) AP1141A (pl)
AR (1) AR011697A1 (pl)
AT (1) ATE295150T1 (pl)
AU (1) AU728461B2 (pl)
BG (1) BG64690B1 (pl)
BR (1) BR9808060B1 (pl)
CA (1) CA2286126C (pl)
CO (1) CO4980849A1 (pl)
CY (1) CY2569B1 (pl)
CZ (1) CZ298008B6 (pl)
DE (1) DE69830154T2 (pl)
EA (1) EA001990B1 (pl)
EE (1) EE03996B1 (pl)
ES (1) ES2239802T3 (pl)
HK (1) HK1022853A1 (pl)
HN (1) HN1998000045A (pl)
HR (1) HRP980154B1 (pl)
HU (1) HU225600B1 (pl)
ID (1) ID29294A (pl)
IL (1) IL131917A0 (pl)
IS (1) IS2515B (pl)
MY (1) MY116242A (pl)
NO (1) NO326719B1 (pl)
NZ (1) NZ337798A (pl)
PA (1) PA8449301A1 (pl)
PE (1) PE61699A1 (pl)
PL (1) PL190505B1 (pl)
PT (1) PT969815E (pl)
RS (1) RS49772B (pl)
SI (1) SI0969815T1 (pl)
SK (1) SK283417B6 (pl)
SV (1) SV1998000040A (pl)
TW (1) TW536403B (pl)
UY (1) UY24930A1 (pl)
WO (1) WO1998042321A2 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ333099A (en) 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
US6018044A (en) * 1998-01-02 2000-01-25 Roche Vitamins Inc. Light screening compositions
US6432966B2 (en) * 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
JP2003039582A (ja) * 2001-07-19 2003-02-13 Three M Innovative Properties Co 湿潤防滑性シート及び湿潤防滑構造体
US6855346B2 (en) * 2001-10-05 2005-02-15 Tzu-Sheng Wu Pharmaceutical composition having prophylactic effects on lamivudine-related disease relapse and drug resistance and methods of using the same
TWI275392B (en) * 2002-04-08 2007-03-11 Bristol Myers Squibb Co Low dose liquid entecavir formulations and use
WO2004075913A1 (ja) 2003-02-28 2004-09-10 Chugai Seiyaku Kabushiki Kaisha タンパク質含有安定化製剤
US20040228804A1 (en) * 2003-05-16 2004-11-18 Jones Alonzo H. Nasal administration of xylitol to a non-human mammal
PE20060484A1 (es) * 2004-07-14 2006-07-06 Ucb Farchim Sa Preparaciones farmaceuticas liquidas que comprenden un compuesto de benzhidril piperizina
CN100427082C (zh) * 2005-08-02 2008-10-22 盛华(广州)医药科技有限公司 羟基苯甲酸酯及其类似物在制备预防和治疗病毒性感染药物中的应用
WO2009092002A1 (en) * 2008-01-17 2009-07-23 Duquesne University Of The Holy Spirit Antiretroviral drug formulations for treatment of children exposed to hiv/aids
RU2587782C1 (ru) * 2015-01-19 2016-06-20 Общество с ограниченной ответственностью "Трейдсервис" Стабильная фармацевтическая композиция ламивудина

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) * 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
DK0513917T4 (da) * 1991-05-16 2001-06-25 Glaxo Group Ltd Antivirale kombinationer indeholdende nukleosidanaloger
GB9111902D0 (en) * 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9503850D0 (en) * 1995-02-25 1995-04-19 Glaxo Group Ltd Medicaments
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
GB9605293D0 (en) * 1996-03-13 1996-05-15 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
AP1141A (en) 2003-01-29
EE03996B1 (et) 2003-04-15
EP0969815B1 (en) 2005-05-11
HUP0002982A3 (en) 2001-12-28
CZ340399A3 (cs) 2000-04-12
IS2515B (is) 2009-06-15
HN1998000045A (es) 1999-03-19
NZ337798A (en) 2001-03-30
HRP980154B1 (en) 2002-06-30
EP0969815A2 (en) 2000-01-12
IL131917A (en) 2001-01-11
HK1022853A1 (en) 2000-08-25
HU225600B1 (en) 2007-05-02
UY24930A1 (es) 2000-10-31
KR100484695B1 (ko) 2005-04-22
JP2001501974A (ja) 2001-02-13
SI0969815T1 (pl) 2005-08-31
WO1998042321A2 (en) 1998-10-01
TW536403B (en) 2003-06-11
CN1191061C (zh) 2005-03-02
CO4980849A1 (es) 2000-11-27
BR9808060B1 (pt) 2009-05-05
NO994619D0 (no) 1999-09-23
PL190505B1 (pl) 2005-12-30
CA2286126C (en) 2003-08-12
JP3264937B2 (ja) 2002-03-11
BR9808060A (pt) 2000-03-08
ATE295150T1 (de) 2005-05-15
BG64690B1 (bg) 2005-12-30
US6004968A (en) 1999-12-21
AU7208498A (en) 1998-10-20
RS49772B (sr) 2008-06-05
MY116242A (en) 2003-12-31
CY2569B1 (en) 2008-07-02
HRP980154A2 (en) 1998-12-31
NO994619L (no) 1999-11-23
EA199900757A1 (ru) 2000-08-28
WO1998042321A3 (en) 1999-01-07
CN1255849A (zh) 2000-06-07
IS5184A (is) 1999-09-17
EA001990B1 (ru) 2001-10-22
DE69830154D1 (de) 2005-06-16
BG103818A (en) 2000-06-30
DE69830154T2 (de) 2005-10-13
ES2239802T3 (es) 2005-10-01
PA8449301A1 (es) 2000-05-24
CA2286126A1 (en) 1998-10-01
AR011697A1 (es) 2000-08-30
IL131917A0 (en) 2001-03-19
HUP0002982A2 (hu) 2001-01-29
PL336038A1 (en) 2000-06-05
SV1998000040A (es) 1999-03-16
PE61699A1 (es) 1999-07-08
YU47799A (sh) 2002-06-19
CZ298008B6 (cs) 2007-05-23
EE9900440A (et) 2000-04-17
ID29294A (id) 2001-08-16
KR20010005624A (ko) 2001-01-15
AU728461B2 (en) 2001-01-11
AP9901657A0 (en) 1999-09-30
SK129999A3 (en) 2000-07-11
PT969815E (pt) 2005-07-29
NO326719B1 (no) 2009-02-02

Similar Documents

Publication Publication Date Title
EP0427246B1 (de) Arzneimittel, welche als Wirkstoff Schwefel enthaltende Carbonsäuren enthalten sowie deren Verwendung zur Bekämpfung von Retroviren
US6004968A (en) Pharmaceutical compositions containing lamivudine
AU770495B2 (en) Medicinal compositions for preventing or treating viral myocarditis
JP3117726B2 (ja) Vx478のようなhivプロテアーゼ阻害剤およびビタミンe―tpgsのような水溶性ビタミンeを含む組成物
JPH0232093A (ja) 抗レトロウィルスジフルオロ化ヌクレオシド類
JP2724711B2 (ja) 医薬品生成物
KR0143410B1 (ko) B형 비루스성 간염치료용 제약학적 조성물
ES2216050T3 (es) Uso de l-carnitina y derivados para reducir niveles de ceramida y potenciar el efecto antiretroviral.
WO1997037661A1 (fr) Medicament de prevention et de traitement des infections virales
US5955498A (en) Agent for prophylaxis and therapy of diseases
US7632853B2 (en) Soluble, stable and concentrated pharmaceutical composition compromising ritonavir and process for preparing thereof
MXPA99008690A (en) Pharmaceutical compositions
CN107648249B (zh) 去半乳糖替告皂甙在制备防治流感病毒感染的药物中的应用
UA60328C2 (uk) Фармацевтична композиція
JPH0551566B2 (pl)
SK284244B6 (sk) Farmaceutický prostriedok na liečenie HIV infekcie na orálne podanie
JPH09508150A (ja) B型肝炎の予防または治療のためのチオケテン誘導体の用途
CN104546685A (zh) 一种齐多夫定糖浆制剂及其制备方法

Legal Events

Date Code Title Description
MK4A Expiry of patent

Expiry date: 20180320